Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Paediatric rheumatology in 2014

Digging deeper for greater precision and more impact in JIA

Nature Reviews Rheumatology volume 11, pages 70–72 (2015)Cite this article

Subjects

Optimizing the management of childhood arthritis requires detailed knowledge of the disease in an individual patient. Advances in 2014 show how in-depth genetic studies and insights into immunopathogenesis could translate into clinical biomarkers and, eventually, individualized therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Treatment options for patients with JIA include MTX as well as biologic agents that target TNF or the IL-6 receptor.

References

  1. Wakil, S. M. et al. Mutation of LACC1 is associated with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.38877.

  2. Brunner, H. I. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205351.

  3. Vogl, T. et al. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat. Commun. 5, 4593 (2014).

    Article  CAS  Google Scholar 

  4. Prakken, B., Albani, S. & Martini, A. Juvenile idiopathic arthritis. Lancet 377, 2138–2149 (2011).

    Article  Google Scholar 

  5. Prahalad, S. et al. Quantification of the familial contribution to juvenile idiopathic arthritis. Arthritis Rheum. 62, 2525–2529 (2010).

    Article  Google Scholar 

  6. Mellins, E. D., Macaubas, C. & Grom, A. A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 7, 416–426 (2011).

    Article  CAS  Google Scholar 

  7. Vastert, S. & Prakken, B. Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 28, 229–246 (2014).

    Article  Google Scholar 

  8. Foell, D. et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266–1273 (2010).

    Article  CAS  Google Scholar 

  9. Bending, D. et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J. Immunol. 193, 2699–2708 (2014).

    Article  CAS  Google Scholar 

  10. Bromberg, M. H., Connelly, M., Anthony, K. K., Gil, K. M. & Schanberg, L. E. Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. Arthritis Rheumatol. 66, 462–469 (2014).

    Article  Google Scholar 

Download references

Acknowledgements

B.P. is supported by EUTRAIN (the 7th Framework programme of the EU), Marie Curie, Network for Initial Training (ITN) grant agreement No 289903, and by the Dutch Arthritis Foundation and the Understanding Childhood Arthritis Network (UCAN-U).

Author information

Authors and Affiliations

  1. Department of Paediatric Immunology & Laboratory for Translational Immunology, University Medical Centre Utrecht, PO Box 85090, Utrecht, 3508 AB, Netherlands

    Berent Prakken

  2. Department of Paediatrics, University of Genova, IRCCS G. Gaslini, Largo G. Gaslini 5, Genova, 16147, Italy

    Alberto Martini

Authors
  1. Berent Prakken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Martini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Berent Prakken.

Ethics declarations

Competing interests

B.P. has received speaker fees and/or has served as independent advisor for Amgen, Danone Research and Novo Nordisk. A.M. has in the past 3 years received honoraria and speakers' bureau fees from AstraZeneca, BMS, Boehringer Ingelheim, GSK, MedImmune, Novartis, Novo Nordisk and Sanofi Aventis; the GASLINI Hospital, of which A.M. is a full-time employee, has received support for the research activities of PRINTO from Abbott, AstraZeneca, Bristol–Myers Squibb, Eli Lilly and Company, 'Francesco Angelini' Foundation, GSK, Italfarmaco, Janssen Biologics B.V., Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma and Wyeth Pharmaceuticals.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prakken, B., Martini, A. Digging deeper for greater precision and more impact in JIA. Nat Rev Rheumatol 11, 70–72 (2015). https://doi.org/10.1038/nrrheum.2014.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.224

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing